Bill C-17 (Historical)

Protecting Canadians from Unsafe Drugs Act (Vanessa's Law)

An Act to amend the Food and Drugs Act

This enactment amends the Food and Drugs Act regarding therapeutic products in order to improve safety by introducing measures to, among other things,
(a) strengthen safety oversight of therapeutic products throughout their life cycle;
(b) improve reporting by certain health care institutions of serious adverse drug reactions and medical device incidents that involve therapeutic products; and
(c) promote greater confidence in the oversight of therapeutic products by increasing transparency.

Business of the House

[Peter Van Loan, Conservative, Leader of the Government in the House of Commons]

Mr. Speaker, let me start by sharing a couple of sentiments with my friend.

First, on this side of the House—speaking for myself at least, and many others, including the Prime Minister—we congratulate the Montreal Canadiens on their success and wish them all the best in the next round, where I am optimistic Canadians will have much to look forward to.

Second, I have to agree with the member about the fact that what we saw today was a preview of what we would see if the NDP were ever to win government. We saw a grilling where the highlight was the question of NDP corruption and abuse of taxpayers' dollars. That is what we could expect to see if the NDP were ever to become government, and because Canadians know that, we will never have to fear it happening.

That abuse of taxpayers' funds goes beyond the question of breaking rules and not following rules. It goes to the whole NDP philosophy that taxpayers' money is there for them, they should get more of it, and they should spend it in every way possible. That is what the NDP is all about.

We in the Conservative Party, on the other hand, have an approach that is focused on a productive, hard-working, and orderly Parliament that respects taxpayers' dollars. As a result, we will continue with our agenda.

I will note the highlight today from the NDP. The NDP was defending itself on charges of improper spending and improperly using taxpayers' dollars for partisan activity. The member did not point out that the NDP's positive agenda was what they were proposing today in the House of Commons on one of the rare days when NDP members actually get to put forward their own policy proposals. It is funny how he says, “That is not the highlight”. I agree with him, because when they do get in power, they will have very little to advocate for.

That said, we on this side do follow the rules, and the rules require that we continue with the NDP opposition day motion for the balance of the day.

Tomorrow we will start the second reading debate of Bill C-27, the veterans hiring act, before we return to our constituencies for a week.

Upon our return we will roll up our sleeves and work hard for Canadians in the final sittings until the summer.

On Monday, May 26, we will consider Bill C-18, which is the agricultural growth act.

On Tuesday, May 27, we will resume the second reading debate on Vanessa's law, Bill C-17, the protecting Canadians from unsafe drugs act.

That will be followed by Bill C-32, the victims bill of rights act at second reading.

The next day will see us continue our productive, hard-working, and orderly agenda by returning to the second reading debate on Bill C-24, the strengthening Canadian Citizenship act. As hon. members might recall, the New Democrats proposed a second reading amendment to block the passage of this important bill.

On Thursday, May 29, we will continue the second reading debate on Bill C-22, the Energy Safety and Security Act. After that debate concludes, we will consider Bill C-6, the Prohibiting Cluster Munitions Act, at report stage. Finally, we will consider Bill C-10, the Tackling Contraband Tobacco Act, at report stage and third reading on Friday, May 30.

As you can see, Mr. Speaker, we still have a lot of work ahead of us this spring.

Food and Drugs Act

[Rosane Doré Lefebvre, NDP, Alfred-Pellan, QC]

Mr. Speaker, I thank the hon. member for Oakville for his comments. I must say, I am very happy that the bill contains provisions to change the current system.

As I already mentioned, the NDP will vote in favour of Bill C-17, and we look forward to discussing it in committee in order to make some changes that are even more significant. I appreciate the comments from the member for Oakville.

[Rosane Doré Lefebvre, NDP, Alfred-Pellan, QC]

Mr. Speaker, today I am honoured to be speaking to Bill C-17, An Act to amend the Food and Drugs Act.

Before I begin, I would like to thank the hon. member for Oakville for the courage and determination he has shown in having this bill introduced in the House and in supporting it, as it touches him personally.

It is very important that we debate such a sensitive and important bill. The federal government must shoulder its responsibilities regarding the Food and Drugs Act. It is good that we are debating this today. I would like to assure the hon. member opposite, the member for Oakville, that the official opposition will be supporting the bill.

I understand that the minister would be open to amendments. We would be more than pleased to participate in the debate and put forward amendments to Bill C-17 so that it can be improved and so that we create the best legislation possible. In that way, we can keep cases like Vanessa's and so many others from happening in Canada.

The NDP will be supporting Bill C-17, which makes several key improvements to drug safety laws.

First, it allows the government to recall drugs or order the distributor to take corrective action to remedy the problem with the drug. That is an extremely important element, one that I will come back to later on in my speech.

Second, it allows the health minister to order a manufacturer or importer to modify the label of a drug to update the side effects or health risks associated with it. The minister can also order a review of the drug and require that a copy of the review be given to the department. In addition, the minister can require manufacturers to update Canadian information about the risks associated with their drug even if the safety risks were discovered in other countries

This bill is a good first step in establishing a comprehensive drug plan and in setting the course for our society on this issue. After calls from many health care professionals and advocates, this bill will finally grant the health minister the necessary power to pull unsafe drugs from the market and ensure better labelling of possible adverse effects of drugs.

We support this legislative measure and we hope that even more practical measures will follow. We support this bill, but there is still much to be done to improve drug safety measures. We will therefore propose amendments to improve this bill in committee.

We hope that our efforts will lead to a comprehensive piece of legislation that will include follow-up by Health Canada on adverse drug reactions, increased transparency with regard to the assessment of prescription drugs and a better system for communicating the risks associated with drugs to health care professionals and patients, in particular.

As I mentioned, this bill will make it possible for the government to compel manufacturers to recall drugs and order distributors to take corrective action to resolve problems with their products. In this regard, at the end of her speech, my colleague from Halifax gave the example of a mistake that was made in 2011 by the manufacturer of Alesse 28.

Alesse 28 is a type of birth control pill that generally works on a 28-day cycle. Women take the product for the first 21 days and then they take a placebo for the remaining seven days. The placebos are often just sugar pills. The problem that occurred had to do with the content of the pills. Rather than containing 21 birth control pills, a package of the product contained two weeks' worth of placebo pills.

Obviously, this can have a rather serious impact on a woman's menstrual cycle. I do not necessarily want to get into the details of how the menstrual cycle works, but having good birth control that works is really very important.

Since 1969, the year in which woman were given access to oral contraceptives, thousands of women in Canada and throughout the world have been using this method of birth control. I have used it myself, as many other female members of the House likely have, and many Canadian women use it.

It is an extremely important part of our family planning, for all sorts of reasons. There are various reasons why women use birth control. A drug that does not have the anticipated effect can have an extremely harmful impact on the health of women and on family planning.

These thousands of women trust in the system, in our health care system and in the drug manufacturers. The women affected by this problem experienced low hormone levels, which caused a number of problems. The main purpose of the product is to prevent ovulation. The placebos prevent that prevention, so to speak, and allow the woman to ovulate. That can have a serious impact on family planning.

Bill C-17 could do something about this. How did people find out about this mistake? Pharmaceutical companies were certainly not forthcoming about it. Pharmacists were the ones who sounded the alarm after noticing that there was a problem with the drugs they were selling. If the pharmacists had not spoken up and told people about the situation, the pharmaceutical companies surely would not have told anyone. There is no telling how far the situation might have gone.

It is good to know that with Bill C-17, new provisions will enable the federal government to do something. Currently, it cannot do anything about situations like that. The government has no power to act. It is very important to create legislation to address these situations. I am speaking on behalf of many women who believe that the federal government should have a say in the matter. We have to make sure that women have access to the best possible drugs, the best possible oral contraceptives.

Once again, I would like to thank the member for Oakville for introducing this measure in his bill.

As I said, we will support this bill at second reading, and we will probably put forward a number of amendments in committee just to make it better. That said, we do think that it is a step in the right direction.

We would like to see several more things in this bill. I know that I will not be able to go into detail because my time is almost up, but the bill ought to include a number of measures, such as optimal prescribing practices to ensure that Canadians are being prescribed the most appropriate drugs. Public disclosure of clinical trial results is also important because, in Canada, the results of numerous clinical trials are never published or made available to the public. We are also asking the government to strengthen the common drug review.

In closing, I would like to say that Bill C-17 is a step in the right direction and that the federal government has to step up to its responsibility with respect to the Food and Drugs Act. I am also pleased that the government is so open to amendments that might be put forward. I am very happy that we are talking about this bill in the House. I can assure the member for Oakville that we will vote in favour of the bill and that we will make sure it is the best it can be.

[Terence Young, Conservative, Oakville, ON]

Mr. Speaker, I am very pleased to stand in the Parliament of Canada today to endorse Vanessa's law, the protecting Canadians from unsafe drugs act.

I am honoured to be a member of the first Canadian government ever to tackle the insidious and largely hidden problem of the injuries and deaths routinely caused by prescription and over-the-counter drugs. I thank two consecutive ministers of health and the Prime Minister, who acted boldly to make Canadians safer, directly taking on the most influential industry in the world, big pharma, and the status quo in the practice of medicine, which has been corrupted by that industry.

Today is a milestone for me and the Young family as well as for the Government of Canada. I stand here today due to a tragedy in my family that took place exactly 14 years ago last week, on Saturday, March 18, 2000. Without warning, our 15-year-old daughter Vanessa, for whom this act is named, fell down dead in front of me, her heart stopped by the Johnson & Johnson blockbuster prescription drug Prepulsid, a drug we later discovered she should have never been given. Despite emergency ambulance services and the valiant efforts of doctors at two hospitals, Vanessa never regained consciousness and died the next day. We never had a chance to say goodbye.

On March 20, 2000, I began the journey that led me to the House of Commons this morning. The facts of this tragedy shock every layperson who hears them, yet I was to quickly discover that the insiders, the doctors, researchers, and people of big pharma, were never shocked. They knew all along that potentially life-threatening drugs were being pushed on patients with non-life-threatening conditions, as the drug business had become all about Wall Street, and they were benefiting financially big time.

Our doctors are groomed through highly sophisticated big pharma relationship marketing programs. They get their first free lunch the first week of medical school. They then go on to naively accept up to $4 billion a year in North America in gifts, lunches, dinners, event tickets, and free trips from drug companies, imagining that those debts of gratitude do not change their prescribing behaviour. Sometimes I would ask them, “Do you think a drug company takes a bunch of doctors to Bahamas out of kindness?” They also accept and hand out, without any prescription, $3 billion a year worth of free samples of new prescription drugs, creating debts of gratitude in their own patients. It is a dangerous practice, because patients get no safety warnings.

In November 2010, 18-year-old Brennan McCartney, of Bolton, Ontario, took a free sample of the anti-depressant Cipralex, with no safety warning about suicide, which is written right on its label. He went out and hanged himself from a tree in a public park.

Four doctors knew that Vanessa was taking Prepulsid for bloating and a mild form of bulimia, yet neither Vanessa nor we, her parents, were given any warning that the drug was already responsible for 80 deaths. Why? How could this happen to the beautiful, innocent child her doctor described as the picture of perfect health? How could four doctors, people we totally trusted, allow Vanessa to continue to take a drug that could stop her heart?

I began the next day to find out how Vanessa died and why, and I have uncovered many dark secrets. Prescription drugs, taken as prescribed, the right way, are the fourth leading cause of death in North America. There are over 106,000 deaths a year just in hospitals and another 100,000 outside hospitals. That is about 20,000 deaths a year in Canada and 200,000 serious drug injuries.

The drug industry representatives who infest Parliament Hill love to talk about when doctors make errors or when patients use the wrong drug or take too much of a drug. What they never talk about is when a drug used the right way kills or injures a patient, causing 10,000 deaths a year in Canada. In fact, one in nine patients in Canada who goes into hospital will suffer a serious adverse drug reaction in hospital.

All drugs are poisons. Any drug can be toxic; it is just a matter of dose. All drugs cause adverse effects. Some people think over-the-counter drugs are totally safe, yet ordinary Tylenol, acetaminophen, causes hundreds of deaths every year and more cases of acute liver failure than all other medications combined. Too much taken with alcohol can destroy one's liver. Has anyone's doctor ever mentioned that?

Ordinary aspirin and ibuprofen cause thousands of deaths every year across North America, mostly from internal bleeding, yet most patients have never heard this. Why not? There is only one reason. It is because the people who market the drugs, big pharma, do not want patients to know the truth. That would reduce sales.

What happened to Vanessa and Brennan McCartney could happen to anyone who takes drugs without proper safety warnings. Nothing significant has changed since 2000 except the current introduction of plain language labelling for drugs and this bill.

Vanessa's law will empower the Minister of Health to compel drug companies to change their labels to clearly reflect the true risk to patients from their drugs. Patients would be empowered to make informed decisions to take the drugs or not. Patients could then take drugs only when they are relatively safe.

Twenty-seven drugs have been pulled from the Canadian market since 1997 for injuring and killing patients. Prepulsid is one. Another, the painkiller Vioxx, killed 55,000 to 65,000 people worldwide in four years on the market. Why do most Canadians not know that? It is because the drug companies never admit that their drugs have harmed anyone. They spend months and months investigating serious reactions, and then they attempt to blame the patient. They conclude that patients must have taken too much, that they must have had a previously undiagnosed and unknown conditions, or that it must have been a combination of the company's great drug with the patients' other drugs. They then contraindicate their drug with the other drug and change the print on a 50-page label, which most doctors and few patients ever read. Then they carry on promoting it, including for off-label use, meaning for conditions for which it was never proven safe or effective.

Doctors can prescribe any drug at any time for any condition for any patient, even if it is never proven safe for such use. In fact, 70% of doctors prescribe off-label at least some of the time. Modern medicine can be the wild west.

That is what the Johnson and Johnson detail reps did to Vanessa's doctors. They whispered to them that Prepulsid was effective for teens who threw up after meals, yet it was contraindicated and dangerous for anyone throwing up. That was the official warning, but they did not whisper that in her doctors' ears, because Prepulsid was heading for blockbuster status. It was a golden calf, with $1 billion a year in sales.

Just before Health Canada is about to take action to expose risks, the drug companies will pull drugs off the market voluntarily. That way they can keep selling them in over 100 other countries in the world, because they have never admitted that the drug could cause anyone harm. That is the drug business.

Vanessa's law will give the Minister of Health the power to order drugs that present as serious or imminent risk of injury or death off the market without delay. Had this been done with Prepulsid, instead of negotiating over weeks with Janssen-Ortho, Prepulsid would have been recalled. Vanessa would be alive today, along with many others.

Drug companies refuse to provide the true number of serious adverse drug reactions to Health Canada. They report what they hear about, but what does not appear on their label is this crucial fact: only 1% of serious adverse drug reactions are ever reported by doctors. Whatever the number is on the label can usually be multiplied by 100 to get the true number, which the drug companies never do.

Most doctors never report adverse drug reactions. Outside of the doctors I have worked with in prescription drug safety, I have never met a doctor who has reported one.

Despite my advocacy for over 14 years that reporting adverse drug reactions saves lives by providing a widely based early warning system for dangerous drugs, the Canadian Medical Association and the Ontario Medical Association, to this day, do not support making adverse drug reaction reporting a standard practice or mandatory. Doctors are fooled by their own negligence in not reporting life-saving information. Patients die as a result.

On October 9, 2011, 18-year-old Allison Borges of Oakville was found in a stairwell of her residence at Queen's University, dead, having suffered a pulmonary embolism caused by Apri 28, a birth control pill that her doctor told her was safe. She received no warning that the newer birth control pills are more likely to cause deadly blood clots than the older ones.

No woman should be given a birth control pill without a clear warning about deadly blood clots, yet it happens all the time. Sadly, 18 year old Marit McKenzie of Calgary suffered the same fate in January 2013. Had Vanessa's law been in place and implemented, both deaths would have been prevented.

Vanessa's law will impose, for the first time, a duty on health care institutions to report all serious adverse drug reactions, which will capture any adverse drug reaction that causes patients to end up in a hospital or clinic. That will hopefully capture the majority of serious adverse drug reactions so that officials can be alerted to dangerous drugs faster. This will help get them off the market faster and save lives. We must rely on the provinces to persuade doctors themselves to stop covering up adverse drug reactions caused by their prescriptions.

Over half the serious side effects of new drugs will not be revealed during testing. In fact, in the first two years on the U.S. market, one in five, or 20% of new drugs, will be pulled off the market for injuring or killing patients or will be assigned the highest level of warning, a black box warning, to be handed to each patient with the prescription. It is a more effective warning than Canada has ever had and that, under Vanessa's law, it will have.

In May 2007, 18-year-old Sara Carlin of Oakville stopped taking her prescription anti-depressant Paxil abruptly. Then she doubled up, to catch up, two days later. She had no warning that Paxil could cause suicidal ideation and akathesia in those circumstances. Her father found her the next day, hanging by her own hand, in the basement of their home. Neither Sara nor her family had heard about the five “Dear Doctor” letter warnings Health Canada had sent out about Paxil.

Vanessa's law will for the first time allow the minister to order assessments of a drug, including conducting tests or studies and reporting them to Health Canada, and to change the drug labels to better reflect the newly identified risks. Proposed regulations for drug labelling will empower Health Canada to order drug companies to issue labels and patient information leaflets that are written in plain language, with the rare but dangerous potential side effects listed up front, on page one, where patients need to see them. Patient can then decide if they want to accept those dangers or not.

In 2003, Dr. Allen Roses, worldwide vice-president of genetics at GlaxoSmithKline, the world's second largest pharmaceutical company, made this statement at a scientific meeting, thinking there were no journalists present: “The vast majority of drugs—more than 90 per cent—only work in 30 or 50 per cent of the people”.

What this means is that with a worldwide market of about $800 billion for prescription drugs, as much as $400 billion a year is not only wasted but millions of patients are exposed to dangers with no chance of benefiting.

According to the Canadian Pharmacists Association, between $2 billion and $9 billion a year is wasted in our drug system. This means that as patients increasingly reject the drug industry's pill for every ill, our health care system would save billions of dollars, hopefully to be invested in preventive care.

Seventy percent of adverse drug reactions are preventable. They are caused by the aggressive over-marketing of drugs, misleading sales pitches, and the covering up of harms that victimize patients.

How could any moral corporate executive push a drug that could stop a child's heart to treat bloating? That is exactly what the executives at Johnson and Johnson's drug arm Janssen-Ortho did, and they broke the law in doing it. It is quite normal in the drug business.

Drug safety is about one thing: does the potential risk of this drug outweigh the potential benefits for me? Yet the big pharma companies do everything they can to make sure that patients have no way to answer that question. They exaggerate the benefits and they hide the risks.

I know that this sounds outrageous. It sounds like a father who lost his daughter and then lost his objectivity, so let me give a few factual examples of where big pharma companies have openly admitted to crimes to increase sales of their drugs.

In 2012, GlaxoSmithKline, the people who made our H1N1 vaccine, paid a fine of $3 billion, the highest in history, to U.S. governments for illegally marketing three drugs: Paxil, an anti-depressant, which causes suicides; Avandia, a diabetes drug that causes heart attacks and strokes; and Wellbutrin, another anti-depressant with similar adverse effects. Yet GlaxoSmithKline had grossed $26 billion in sales for these three drugs in the previous six years. With markups on drugs at more than 100% and 1000%, a $3 billion fine is really just the cost of doing business for GlaxoSmithKline. It is kind of like a speeding ticket.

Shortly after Vanessa died, I asked adverse drug reaction expert Dr. Neil Shear, in Toronto, why drug companies do not take dangerous drugs like Prepulsid off the market. Here is what he replied: “In the drug industry, killing people is not bad for business. As long as it's not too many”. Nothing has changed since that time. Big pharma companies put the legal costs for injuries and deaths right in their business plans.

Here are some more examples of big pharma corporate criminals. I will read a short list from a list that could be pages long.

Merck has paid $1.6 billion in settlements since 2008, in part for paying illegal kickbacks to health care providers. Ely Lilly paid $1.3 billion in 2009 for illegally promoting Zyprexa, leading to the deaths of many seniors. Novartis paid $422 million in 2010 for off-label promotion of Trileptal. Forest Labs paid $313 million in 2010 for off-label promotion of Celexa and Levothroid. Allergan paid $825 million in 2010 for off-label promotion of Botox. AstraZeneca paid $520 million in 2010 for misleading doctors and patients about the safety of Seroquel. The list goes on, and these are just since 2008.

The question is, how do the big pharma companies get away with this?

They have power and influence. They are some of the wealthiest companies in the world and have no loyalty to any country, but, above all else, despite the thousands of deaths, no big pharma executive has ever gone to jail.

Imagine if murderers, rapists, or extortionists could simply negotiate payments with some government official to keep out of jail and to keep on doing what they are doing. The only way these companies will ever stop their corrupt practices is: one, if the practices become unprofitable; and, two, if those responsible face real jail time. Vanessa's law, for the first time, would impose tough new penalties for unsafe products, increasing fines from $5,000 a day to $5 million a day and including jail time for up to two years. That is the only way to actually get their attention and change their ways. And if these serious violations are caused intentionally, court-imposed fines could be unlimited.

My hope is that when life-threatening dangers are intentionally covered up, judges will fine offenders the entire amount of their sales of their blockbuster drug, or more, because nothing else will change their practices.

Vanessa's law would be the beginning of the end for the unscrupulous and corrupt marketing practices in big pharma companies in Canada. It would no doubt reduce drug injuries and deaths in Canada by thousands. It is much needed and it is long overdue. We can never have Vanessa back, in this life, or Sara Carlin, or Allison Borges, or Brennan McCartney, or Marit McKenzie, but we can change things moving forward. We can do what governments are supposed to do: protect vulnerable people.

Vanessa's law represents the highest calling of a government, in my view. When the death of an innocent child can lead to definitive action by the Government of Canada to help prevent others from the same fate, our democracy is at its best.

Every school day, across Canada, millions of children sing:

From far and wide,
O Canada, we stand on guard for thee.

However, that promise has to be a two-way street.

Vanessa Young would be proud to see that with Bill C-17, Canada is standing on guard for its school children, its seniors, and its other vulnerable patients.

[Rona Ambrose, Conservative, Minister of Health]

moved that Bill C-17, An Act to amend the Food and Drugs Act, be read the second time and referred to a committee.

Business of the House

[Peter Van Loan, Conservative, Leader of the Government in the House of Commons]

Mr. Speaker, I first want to say here what I said on Twitter last week; that is, I would like to thank the hon. member for Skeena—Bulkley Valley for the working relationship that we have enjoyed over the last couple of years. I wish him well with his new critic responsibilities.

Now let me thank the hon. member for Burnaby—New Westminster for his first Thursday question. I welcome the hon. member to his new role as the House leader of the official opposition. I have been told by my staff that he is the tenth House leader from across the aisle with whom I have had the pleasure of working.

While I am confident that his predecessor has briefed him on our government's approach toward facilitating a hard-working, productive, and orderly House of Commons, I see that he has already fallen into one of the grievous errors of his predecessor. For a whole bunch of reasons, I would encourage him to look in some detail at the House of Commons rules and procedures.

For example, he was concerned with time allocation and referred to it again as limiting debate, yet when he reviews the rules, as I know he is going to, and I know he will do that with some enthusiasm in the near term, he will notice citation 533 of Beauchesne's Parliamentary Rules and Forms of the House of Commons of Canada , sixth edition, which reminds us that:

Time allocation is a device for planning the use of time during the various stages of consideration of a bill rather than bringing the debate to an immediate conclusion.

That is what we have always tried to do here: schedule debates so that we can make decisions, have fair and adequate debate, and give members of Parliament an opportunity to decide questions. It is not to curtail debate; it is to schedule and facilitate decisions being made. I hope that the member will have regard for those rules, something that had escaped his predecessor.

However, I should say that I do look forward to working with him on our business in the future. That said—and I hope that he will not take personal offence to this—in our scheduling of these matters, we will continue to work off of the Gregorian calendar, not the Julian calendar.

Today, we will continue the third reading debate on Bill C-5, the Offshore Health and Safety Act. Tomorrow, we will start the second reading debate on Vanessa’s law, Bill C-17, the protecting Canadians from unsafe drugs act. Monday will see the third day of second reading debate on Bill C-20, the Canada-Honduras Economic Growth and Prosperity Act.

That is one that I know he is a great supporter of.

Tuesday, April 1, shall be the first allotted day. It being April 1 after all, I assume that the NDP will ask us to debate one of its economic policies.

Finally, starting on Wednesday, we will debate our spring budget implementation bill to enact many of the important measures contained in economic action plan 2014, our low-tax plan for Canadians, as we make further progress on balancing the budget in 2015.

I might also add that with regard to the grain situation, Bill C-30 is now before the House. There have been very positive discussions among the parties to date. I hope that they will lead further to being able to have that bill passed through at least second reading on a fairly constructive basis. I hope those discussions will yield fruit, in which case there might be some change to the schedule I have presented to the House today.

[Peter Van Loan, Conservative, Leader of the Government in the House of Commons]

Mr. Speaker, I thank the hon. whip for the opposition for her very kind comments about the abilities on this side of the House with regard to procedure. Of course, I am only as good as the team that I have.

However, I will say that one thing I have tried to outline and to make clear over some period of time is that the use of time allocation is very distinct from the use of closure. We have chosen an approach in this government to use time allocation as a scheduling device to set an amount of time that we believe is appropriate for debate on any particular issue, which, as the hon. member in her own comments confirmed, in some cases results in even more time being allocated than is necessary for debate.

One of the benefits, though, is that the time does not have to be used. If all speakers complete their discussion of the subject, the debate can collapse and we can move on to other matters. So, really, no time is to be lost from that approach. It is a very positive thing, one that allows certainty for the benefit of all members about how much debate we will have, when votes will happen, and when decisions will be made. That is the most important thing for us in our work up here: making decisions and getting the job done.

As for this morning, I know that the NDP keeps seeing conspiracies and ghosts behind curtains, particularly the House leader for the NDP, who has that concern.

I think everyone knows that the only time one can move these time allocation motions—and we do not need to have a great command of the Standing Orders to know this—is at the start of government orders, at the start of the day. So I really had no choice.

However, the committee had considerable flexibility, which it did exercise. There was no conspiracy. There was no obstruction.

I hope that the opposition House leader will take the benefit of the two weeks to calm down, hopefully look around, see that there are no people waiting behind every curtain and every tree, out to get him, and that some of the conspiracies he imagines are simply not there. It will lower his blood pressure. It will make his life much more comfortable, in total.

I know that the opposition whip will share that advice from me, with him.

This afternoon we will continue debating Bill C-20, Canada-Honduras Economic Growth and Prosperity Act, at second reading.

Tomorrow, we will conclude the second reading debate on Bill C-25, Qalipu Mi'kmaq First Nation Act.

Then, we will return to our constituencies, where we will have a chance to reconnect with our real bosses.

When we return on Monday, March 24, the House will have the seventh and final allotted day. At the end of that day, we will consider the supplementary estimates, as well as interim supply, so that these bills will be able to pass through the other place before the end of our fiscal year.

The government's legislative agenda for the balance of that week will focus on protecting Canadians. Tuesday, March 25 will see us start the second reading debate on Bill C-22, the energy safety and security act, a bill that will implement world-class safety standards in the offshore and nuclear sectors. That evening we will finish the debate on the motion to concur in the first report of the foreign affairs committee respecting the situation of Jewish refugees.

On Wednesday, March 26, we will consider Bill C-5, the offshore health and safety act, at report stage and third reading. This bill will complement legislation already passed by the provincial legislatures in Nova Scotia, and Newfoundland and Labrador, given the shared jurisdiction that exists in the offshore sector.

On Thursday, March 27, we will have the fourth day of second reading debate on Bill C-13, the protecting Canadians from online crime act. Through this bill, our government is demonstrating its commitment to ensuring that our children are safe from online predators and online exploitation.

Finally, on Friday, March 28, I hope that we will be able to start the second reading debate on Bill C-17, the protecting Canadians from unsafe drugs act, also known as Vanessa's law.

National Lyme Disease Strategy Act

[Elizabeth May, Green, Saanich—Gulf Islands, BC]

, seconded by the hon. member for Oakville, moved that Bill C-442, An Act respecting a National Lyme Disease Strategy, be read the second time and referred to a committee.

She said: Mr. Speaker, today I am very honoured to introduce this bill for a national strategy on Lyme disease at second reading. When we are able to work together as members of Parliament, anything is possible.

Today I stand here with the great honour of presenting a bill in my name. If I could, I would remove my name and put the names of all of us on it. This is a truly non-partisan effort, and this is reflected in the process of this legislation in the House so far.

At first reading, in June 2012, the seconder of my bill was my friend the hon. Liberal member for Etobicoke North, who has been very active on many health issues. Today I have the enormous honour of having my bill seconded by the hon. member for Oakville, himself a champion on a number of health issues. I commend him and the Minister of Health, in fact all of the Conservative members, for bringing forward Bill C-17, An Act to amend the Food and Drugs Act, Vanessa's law. I look forward to seeing that legislation made into law. These are important steps, which prove that individuals can change public policy, as I hope we will here.

By coincidence, the hon. member for Oakville has also taken a stand on the Lyme disease issue, having written a foreword to a Canadian book called Ending Denial: The Lyme Disease Epidemic.

In this non-partisan spirit, the official opposition, the New Democratic Party, was the first party to signal full support for my bill. The New Democratic Party health critic, the hon. member for Vancouver East, signalled some time ago that I could count on her party's support. It means a tremendous amount to me personally to have this support. It acknowledges the importance of this legislation.

The hon. member for Edmonton—Spruce Grove, the Minister of Health, has herself been very willing to work with me, which means the bill has the potential for success. We have sat down and worked over this bill, and there are some amendments that I would expect to see in committee. I do not regard them in any way as other than helpful. This bodes well for our ability to work together to make a difference on this issue.

What is this issue? Everyone in the Chamber is now familiar with the fact that Lyme disease is spreading. It is spread through a very specific bacteria that is carried by ticks, often blacklegged ticks or deer ticks, and it is now spreading to other species of ticks. The bacteria Borrelia burgdorferi is a bacteria that brings with it both a potential personal tragedy and a very troubling set of symptoms for diagnosis.

As I have said, this disease is spread through ticks. As we have seen, this disease can be delivered to other areas through the agency of birds. The range in which these ticks occurs across Canada has been spreading, and it is part of the increase in vector-borne diseases that are anticipated in relation to global warming and the climate crisis.

We know there are more cases of the disease. It was shocking to many, when in the summer of 2013, the Centers for Disease Control and Prevention, in Atlanta, Georgia, issued a revised estimate of Lyme disease in the United States. Its new estimate increased the prevalence of Lyme disease ten-fold, reporting that the previous year's 30,000 cases were probably 300,000. This is a timely reminder to us in Canada that the incidence of Lyme disease is spreading.

To the credit of Health Canada, since 2009 Lyme disease has been a reportable illness in Canada. There is no question that we know it exists in Canada, and health professionals have a mandatory duty to report a diagnosis of Lyme disease. We are also aware that it is under-reported. Currently any medical practitioner who diagnosis Lyme disease has a responsibility to inform the provincial health authorities, who in turn report this to the Public Health Agency of Canada. At this point, only 310 cases have been reported across Canada.

I am sure my colleagues on all sides of the House know that the number of cases is somewhat low, just in terms of our own anecdotal experience of constituents who have Lyme disease, and from the number of petitions we have received in this place from people urging us to find a solution and urging better treatment and a cure. We cannot estimate exactly how low that is, but as in the United States, I think we will find that as we increase awareness we will have a clearer understanding of the incidence of the disease.

Let me review quickly what the bill would do. This is a bill to deal with the threat of Lyme disease, but it does it in a couple of different ways. The bill's goals are to create a national surveillance system dealing with the problem that I just mentioned; we do not always have good information on exactly where the ticks are spreading and how prevalent they are.

The other area that is important is to get a handle on better awareness, perhaps national standards, or at least a sharing of best practices, to understand the challenges of diagnosis and treatment.

The bill calls for:

3.(b) the establishment of guidelines regarding the prevention, identification, treatment and management of Lyme disease, including a recommended national standard of care that reflects current best practices for the treatment of Lyme disease;

It also calls on the Minister of Health, working with others, to create a national program of educational materials to increase public awareness, but also to assist medical professionals. The process by which this would take place is that once the bill has come into force, there would be a mandatory obligation on the minister of health to convene, within six months, a national conference of provincial and territorial ministers of health, as well as the stakeholders, who are described in the bill as representatives of the medical community and patient groups, for the purpose of developing this national framework.

I am very heartened that at this relatively early stage in the consideration of Bill C-442, it has already received the support of important elements within the medical community. I want to cite particularly, and to thank, Eric Mang, director, health policy and government relations for the College of Family Physicians of Canada, who wrote in the fall of 2013 that they support the bill. He stated:

[The College of Family Physicians of Canada] supports further studying the economic and health impacts of Lyme Disease to ensure that Canadian physicians have the necessary tools and knowledge at their disposal. Guidelines produced as part of the strategy should include the input of family physicians and be available to all primary health care providers.

Even more recently, on February 27, 2014, I was thrilled to receive a letter from the Canadian Medical Association and its president, Dr. Louis Hugo Francescutti. Coming from the medical community, it is important that I read some of this letter into the record at second reading debate. He wrote the following:

Diagnosis of Lyme disease can be difficult because signs and symptoms can be non-specific and found in other conditions. If Lyme disease is not recognized during the early stages, patients may suffer seriously debilitating disease that may be more difficult to treat. Given the increasing incidence of Lyme disease in Canada, continuing education for health care and public health professionals and a national standard of care can improve identification, treatment and management of this disease. Greater awareness of where ticks are endemic in Canada, as well as information on the disease and prevention measures, can help Canadians protect themselves from infection. A national Lyme disease strategy that includes representation from the federal, provincial and territorial governments, the medical and patient communities can address concerns around research, surveillance, diagnosis, treatment and management of the disease. In addition, public health prevention measures will advance our current knowledge base, and improve the care and treatment of those suffering from Lyme disease.

With the support of those two important associations of medical professionals, the Canadian Medical Association and the College of Family Physicians of Canada, I am encouraged to know that we can work together as members of Parliament from all parties in this place. The approach set out in the bill for a national conference urges federal and provincial jurisdictional responsibility in the health community; the medical community, the doctors, health care professionals, nurses, people who deal with trying to sort out a diagnosis for Lyme disease when it is not always easy; and the patient communities, people who have advocated, who have cried out for help, people for whom this bill represents the first ray of light in what, for many, has been years of suffering. I am enormously encouraged by the support from the medical community.

I want to now turn to the support from the patient community. I would never have thought to put forward a private member's bill on Lyme disease had I not encountered so many Canadians who are suffering from the disease. My first friend who told me she had Lyme disease was Brenda Sterling, of Pictou County, Nova Scotia. From her wheelchair, she told me that she had been bitten by a tick and now she was virtually disabled. I was shocked. I did not know Lyme disease could be so serious when I first met Brenda, but she educated me about it.

Then when I moved to Saanich—Gulf Islands and was living in Sidney, I kept meeting people who were experiencing Lyme disease, some of them kids. It is heartbreaking to know a brilliant, beautiful young woman, Nicole Bottles, who is in a wheelchair and not able to go school. It is not because the wheelchair is a difficulty, but because the Lyme disease, as she says, muddles her brain from time to time. She has trouble concentrating and she has not been able to keep up with her schooling. However, she and her mother, Chris Powell, whom I think have met many of the people in this chamber today, have come to Ottawa and advocated for Bill C-442. They see it as a way to get to better levels of awareness.

I am so grateful to James, Michael, and other young constituents, like Eric, and his family. When I think about why I chose this bill, it had a lot to do with Eric and his family. His father-in-law was a strong supporter of mine, and I wondered how I could ever thank him. I am thankful to Fraser, among many people, for my bringing forward a bill that could try to make a difference in thousands of lives.

As we work toward this bill, let us keep a couple of hopeful things in mind. One is that we should never fear the outdoors. Some people have come to me since this bill was tabled saying, “For Heaven's sake, be careful that we don't create fear of going outside”. I want to emphasize that is not my intention.

I subscribe to the view of some who have described nature deficit disorder as a real threat to our kids. They need to get out and engage with wilderness. They need to be in nature. It increases learning abilities, capabilities, and emotional maturity. It is great for kids to spend time outdoors.

We have become used to the education challenge of a thinning ozone layer, which due to the Montreal protocol is reversing the thinning process. Over the years we have become used to asking what the UV rating is, wearing long-sleeved shirts, remembering to use sunscreen, and wearing a broad-rimmed hat, something that did not occur when I was a kid. These are common-sense prevention measures.

We need common sense to be a part of our daily routine. When our kids go out to play, we need to say, “Tuck your pant legs into your socks”, and when they come in from playing outdoors, to say, “Let me give you a quick check to make sure you haven't picked up a tick”. Those kinds of things are common-sense prevention measures.

The good news when facing Lyme disease is that it is preventable. That is why a federal framework makes so much sense. If we are aware of the disease, and watchful, we will not get it in the first place. However, if we do get it and diagnosis is speedy and correct, the treatment works. The treatment need not take long, and one can recover to a complete state of health and well-being.

Lastly, let us shine a light of hope for those dealing with the challenge of continuing debilitating symptoms. With a real focus and continued research, we can find treatment measures that will work for the entire Lyme patient community.

I am indebted to all of the members who have come here this morning for second reading, and thankful for their support. With their help, this bill will become law.

[Cameron Bishop]

One of the things we do lack is an accountability mechanism for some of the regulators for the companies. I have to say I'm pleased with, for example, Bill C-17, but in that context there's a lot of stuff that could be done to tighten it up, based on the recommendations here, that could make Bill C-17 stronger and could go a little bit of the way to addressing some of the things we've talked about here today.

Vanessa's Law

[Terence Young, Conservative, Oakville, ON]

Mr. Speaker, last Friday, I was proud to join Canada's Minister of Health to announce new patient safety legislation, Bill C-17, the protecting Canadians from unsafe drugs act, subtitled “Vanessa's Law”, named after my daughter, Vanessa Young. In 2000, at age 15, Vanessa's life was sacrificed to maintain the sales of a Wall Street blockbuster drug, Propulsid.

It is difficult to overstate the impact the bill will have for Canadians who take prescription and over the counter drugs. It represents a quantum leap forward in protecting vulnerable patients and reducing serious adverse drug reactions.

Combined with the plain language labelling initiative announced last June, Vanessa's law would: put an end to inadequate safety warnings; empower Health Canada to order unsafe drugs off the market when dangers first become clear; require mandatory adverse drug reaction reporting, creating an early and robust warning system for patients; and, undoubtedly, reduce preventable harm from drugs and save thousands of lives.

Vanessa would be pleased that her loss of life has led to this powerful legislation to prevent similar tragedies in other families.

Food and Drugs Act

[Leona Aglukkaq, Conservative, Nunavut, NU]

moved for leave to introduce Bill C-17, An Act to amend the Food and Drugs Act.

(Motions deemed adopted, bill read the first time and printed)